

International Journal of Antimicrobial Agents

Volume 45/S2 (2015)

Editor-in-Chief

A.M. Geddes, (Birmingham, UK)

Editorial Assistant

J. Merrison, (Oxford, UK); IJAA@elsevier.com

Editors

R. Allaker (London, UK)
S. Barrett (London, UK)
N. Beeching (Liverpool, UK)
R.S. Bhardawaj (Pune, India)
G. Coombs (Perth, Australia)
C. Costelloe (London, UK)
P. Coyle (Belfast, UK)
S.L. Croft (London, UK)
B.A. Cunha (NY, USA)
S. Dancer (Glasgow, UK)
H. Derendorf (Gainesville, FL, USA)
M. Ellington (Cambridge, UK)
M. Enright (London, UK)
A. Ghafur (Chennai, India)
H. Giamarellou (Athens, Greece)
E.J. Giamarellos-Bourboulis (Athens, Greece)
B. Gold (NY, USA)
E. Gotuzzo (Lima, Peru)
J. Gray (Birmingham, UK)
P.-R. Hsueh (Taipei, Taiwan)
S. H. Jeong (Seoul, Korea)
D. Law (Manchester, UK)

V. Lim (Kuala Lumpur, Malaysia)
J. Lipman (Brisbane, Australia)
D.M. Livermore (London, UK)
K.G. Naber (Straubing, Germany)
A. Novelli (Florence, Italy)
A. O'Neill (Leeds, UK)
D. Paterson (Brisbane, Australia)
L. Poirel (Le Kremlin Bicêtre, France)
J. Roberts (Brisbane, Australia)
J.-M. Rolain (Marseilles, France)
R. Saginur (Ottawa, Canada)
A. Seaton (Glasgow, UK)
S. Simjee (Basingstoke, UK)
A. Shibl (Riyadh, Saudi Arabia)
S. Stefani (Catania, Italy)
P. A. Tambyah (Singapore)
A. Tsakris (Athens, Greece)
P.M. Tulkens (Brussels, Belgium)
J. Walochnik (Vienna, Austria)
M. Wang (Shanghai, China)
M. Wootton (Cardiff, Wales)

International Advisory Board

E. Akalin (Istanbul, Turkey)
J. Andrews (Birmingham, UK)
B. Barsic (Zagreb, Croatia)
E. Bergogne-Bérézin (Paris, France)
K.A. Brogden (Iowa City, USA)
K. Bush (Bloomington, USA)
W. Craig (Madison, USA)
E. De Clercq (Leuven, Belgium)
C.B. Del Mar (Queensland, Australia)
D. Denning (Manchester, UK)
R. Feld (Toronto, Canada)
A. Fraise (Birmingham, UK)
J.A. Garcia Rodriguez (Salamanca, Spain)
J. Garau (Barcelona, Spain)
I.M. Gould (Aberdeen, UK)
M.L. Grayson (Melbourne, Australia)
K. Hiramatsu (Tokyo, Japan)
I.M. Hoepelman (Utrecht, The Netherlands)
Niels Høiby (Copenhagen, Denmark)
R.N. Jones (North Liberty, USA)

G. Kahlmeter (Vaxjo, Sweden)
K. Klugman (Atlanta, USA)
H.C. Korting (Munich, Germany)
G. Kronvall (Stockholm, Sweden)
D. Lew (Geneva, Switzerland)
A. MacGowan (Bristol, UK)
F.M. MacKenzie (Aberdeen, UK)
L. Mandell (Hamilton, Canada)
T. Matsumoto (Kitakyushu, Japan)
T. Mazzei (Florence, Italy)
C.E. Nord (Stockholm, Sweden)
M. Pelemis (Belgrade, Serbia)
T.V. Riley (Nedlands, Australia)
F. Scaglione (Milan, Italy)
A.M. Sefton (London, UK)
Jae-Hoon Song (Sungkyunkwan, Korea)
M. Struelens (Brussels, Belgium)
F.C. Tenover (Sunnyvale, USA)
J. Verhoef (Utrecht, The Netherlands)
M. Yagisawa (Tokyo, Japan)



ELSEVIER

AMSTERDAM – BOSTON – LONDON – NEW YORK – OXFORD – PARIS – PHILADELPHIA – SAN DIEGO – ST. LOUIS



The Official Journal of the
International Society of Chemotherapy

© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier B.V. and the International Society of Chemotherapy, and the following terms and conditions apply to their use:

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA).

Derivative Works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions).

Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions).

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Advertising information: Advertising orders and enquiries can be sent to: USA, Canada and South America: Mary Anne Arbolado, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710, USA; phone: (+1) (212) 633 3974; e-mail: m.arbolado@elsevier.com. **Europe and ROW:** Sarah Jane Cahill, Senior Account Manager, Elsevier Ltd., 32 Jamestown Road, Camden, London, NW1 7BY, UK; phone +44 (0) 20 7424 4538; fax: +44 (0) 20 7424 4433; e-mail: s.cahill@elsevier.com

Author enquiries: For enquiries relating to the submission of articles (including electronic submission) please visit this journal's homepage at <http://www.elsevier.com/locate/ijaa>. For detailed instructions on the preparation of electronic artwork, please visit <http://www.elsevier.com/artworkinstructions>. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at <http://www.elsevier.com/trackarticle>. You can also check our Author FAQs at <http://www.elsevier.com/authorFAQ> and/or contact Customer Support via <http://support.elsevier.com>.

For a full and complete Guide for Authors, please go to: <http://www.elsevier.com/locate/ijaa>

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>

Language (Usage and Editing services). Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop <http://webshop.elsevier.com/languageediting/> or visit our customer support site <http://support.elsevier.com> for more information.

Ⓞ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

Printed in Henry Ling Ltd., Dorchester, United Kingdom

International Journal of
Antimicrobial Agents

Volume 45/S2 (2015)

Abstracts from the
10th International Symposium on Antimicrobial Agents and Resistance

Songdo ConvensiA, Incheon, Korea, May 14-15, 2015



ELSEVIER

AMSTERDAM – BOSTON – LONDON – NEW YORK – OXFORD – PARIS – PHILADELPHIA – SAN DIEGO – ST. LOUIS

antimicrobial agents were determined, according to guidelines of CLSI, by an agar dilution method. Molecular characterizations of β -lactamases were performed by PCR amplification, DNA sequencing, and Southern blot analysis. The *bla*_{OXA-418} gene was expressed by a pET-30 system and the gene product was purified by His-Bind column and Mono S column. Steady-state kinetic constants of the purified enzyme were determined by fitting the initial rates directly to the Henri-Michaelis-Menten equation using nonlinear regression with the program DYNAFIT.

Among 38 isolates, one carbapenem-resistant *A. baumannii* harbored a novel variant (*bla*_{OXA-418}) of OXAs, which was encoded by the chromosome. The clinical isolate and its transformant showed resistance to carbapenems (especially to meropenem). Notable changes in MIC values were in line with the respective kinetic parameter differences. OXA-418 was most closely to OXA-228.

OXA-418 was derived from OXA-228 by the five substitutions (Val25Glu, Ser192Arg, Asp201Asn, Glu227Lys, and Asn257Asp; OXA numbering system). Among these substitutions, Asp201Asn and Glu227Lys are new sites for carbapenem resistance among OXA-228-like genes.

P1-GR56

Risk factors of MDR Gram negative bacteremia among hospitalized patients

A. Yonata^{1*}, K. Chen^{2,5}, T. Loho³, M. Abdullah⁴. ¹Internal Medicine Department, Faculty of Medicine, University of Lampung-Abdul Moeloek Hospital, Bandar Lampung, Indonesia, ²Tropical Infection Division, Internal Medicine Department, Faculty of Medicine University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia, ³Clinical Pathology Department, Faculty of Medicine University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia, ⁴Clinical Epidemiology Unit, Faculty of Medicine, University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia, ⁵Center for Research and Integrated Development of Tropical Health and Infectious Diseases, Jakarta, Indonesia

Background: Over the past decade, the numbers of bloodstream infections caused by multidrug-resistant (MDR) Gram-negative bacteria have risen sharply. MDR Gram-negative bacteremia increases not only mortality, but also patient morbidity, length of treatment and hospitalization costs. It is important to identify risk factors of MDR Gram-negative bacteremia among hospitalized patients to prevent these risk factors and to lower the incidence of MDR Gram-negative bacteremia.

Aim: To identify the risk factors of MDR Gram-negative bacteremia among hospitalized patients

Method: Risk factors were identified by a case-control study. Data was collected from inpatients medical record that had positive blood cultures of Gram negative bacteria from 2008-2013. The case group was subjects who had MDR Gram-negative bacteremia, and the control group was subjects who had non-MDR Gram negative bacteremia. All variables that had a value of $p < 0.25$ on bivariate analysis were included in multivariate analysis using logistic regression.

Result: During the study period, there were 131 patients fulfilled the criteria: 42 patients who had MDR Gram-negative pathogen bacteremia (case) and 89 patients who had non-MDR Gram-negative pathogen bacteremia (control group). Based on the bivariate analysis, two variables were statistically significance: history of treatment in ICU/HCU ($p=0.003$) and history of ventilator ($p=0.030$). Further multivariate analysis showed that there was one variable statistically significance, which was history of treatment in ICU / HCU (OR: 3.118; CI 95% : 1.443–6.736; $p=0.004$).

Conclusion: History of treatment in ICU / HCU was risk factor of MDR Gram negative bacteremia among hospitalized patients.

Keywords: bacteremia, Gram negative, MDR, risk factor

P1-GR57

Analysis of the roles of small noncoding RNAs in responses to antibiotics and their applications on eradicating MDR bacteria

T. Kim¹, K.-S. Kim^{1,2*}. ¹Superbacteria Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea, ²Biosystems and Bioengineering programs, University of Science and Technology (UST), Daejeon, Korea

The misuse of antibiotics has resulted in increasing bacterial multidrug resistance (MDR). Small noncoding RNAs (sRNAs), modulators of multiple cellular events, may influence bacterial responses to antibiotics; however, their roles and mechanisms of action remain largely unknown. Here, the susceptibilities of *Escherichiacoli* strains overexpressing each of the 26 known Hfq-dependent sRNAs to major classes of antibiotics were determined. The results suggested that 17 sRNAs modulate antibiotic susceptibility; overexpression of nine of these sRNAs specifically reduced or potentiated antibiotic efficacy. These phenotypes were conserved between species, but the essentialities of the sRNAs were limited. Based on overexpression and knockout studies, the results presented here, firstly, unveil sRNA-mediated modulatory pathways and, secondly, suggest that the sRNAs could be used as biomarkers to identify cephalothin-resistant strains. Furthermore, the sRNAs may potentiate the effect of levofloxacin, allowing the modulation of antibiotic action on MDR strains. In summary, sRNAs have the potential to enable bacteria to adapt smartly to antibiotic challenges via multifaceted approaches.

P1-GR58

Clinical and microbiological characteristics of *Klebsiella pneumoniae* bacteremia in a single center

S.Y. Ryu^{*}, H.A. Kim. Division of Infectious Diseases, Keimyung University, Daegu, South Korea

Background: The aim of present study is to evaluate clinical and microbiological characteristics of *K. pneumoniae* bacteremia in a single center.

Methods: The study was conducted at Keimyung University. All episodes of *K. pneumoniae* bacteremia ($n = 344$) during two 2 year periods (2004-5 and 2012-3) were retrospectively compared.

Results: Of a total of 344 patients, 140 (40.6%) were the first period and 204 (59.4%) were the second period. The frequencies of cardiovascular diseases (47.5% vs. 24.3% $P=0.001$), neurologic diseases (19.8% vs. 10.8% $P=0.035$) were significantly higher in the second period than in the first period. The frequencies of cefotaxime (20.1% vs. 7.1% $P=0.001$), cefepime resistance (19.1% vs. 0% $P=0.001$) and ESBL positivity (19.1% vs. 4.3% $P=0.001$) were significantly higher in the second period than in the first period. But the initial empirical antibiotic use of cefepime (17.9% vs. 0% $P=0.001$), carbapenem (19.8% vs. 2.9% $P=0.001$), vancomycin (12.4% vs. 4.3% $P=0.012$) were higher in the second period than in the first period. In the subgroup analysis, the frequencies of cefotaxime (32.4% vs. 10.6% $P=0.002$), cefepime resistance (30.6% vs. 0% $P=0.001$) and ESBL positivity (31.5% vs. 6.1% $P=0.001$) were higher in the second period than in the first period in the healthcare associated *K. pneumoniae* bacteremia group. But the initial empirical antibiotic use of cefepime (17.9% vs. 0% $P=0.001$), carbapenem (19.8% vs. 2.9% $P=0.001$) were higher in the second period than in the first period in both groups.

Conclusion: The frequencies of antibiotic resistance in the community associated *K. pneumoniae* bacteremia group did not differ between the first period and the second period. But the initial empirical antibiotic use of cefepime (17.9% vs. 0% $P=0.001$), carbapenem (19.8% vs. 2.9% $P=0.001$) were higher in the second period than in the first period in both groups.